TaKaRa
로그인  |   회원가입  |   ID/PW 찾기  
제품명/제품코드
키워드검색
검색
Home > 전제품보기 > Transfection 시약 > 도입물질에 따른 도입시약 > TransIT®-Oligo Transfection Reagent

TransIT®-Oligo Transfection Reagent

-

제조사 제품코드 제품명 용량 가격
(부가세별도)		 비고 사용자매뉴얼
Mirus
 MIR 2164
 TransIT-Oligo Transfection Reagent
관련학술 구매하기 		0.4 ml
 가격문의   ml016_transit_oligo.pdf
Mirus
 MIR 2160
 TransIT-Oligo Transfection Reagent
관련학술 구매하기 		1 ml
 가격문의  
Mirus
 MIR 2165
 TransIT-Oligo Transfection Reagent
관련학술 구매하기 		1 ml×5
 가격문의  
Mirus
 MIR 2166
 TransIT-Oligo Transfection Reagent
관련학술 구매하기 		1 ml×10
 가격문의  

  • Unique Formulation - Maximize transfection performance of oligonucleotides into a wide range of cells.
  • Low Cellular Toxicity - Maintain cell density and reduce experimental biases.
  • High Efficiency Delivery - Achieve high transfection efficiency in cells to ensure experimental success.


Figure 1. The TransIT-Oligo Reagent Achieves High Transfection Efficiency. HeLa cells transfected using TransIT-Oligo Reagent and Label IT Cy™3 and Label IT Fluorescein labeled phosphothioate DNA oligos in complete media for 24 hours.

Figure 2. The TransIT-Oligo Reagent Effectively Transfects a 2'OMe RNA Oligo that Blocks a Cryptic Splice Site. The HeLa-Luc 705 reporter cell line (Kang et al. 1998, 37:6235) used in this study contains a luciferase reporter construct that has the ß-globin 705 intron inserted into the luciferase ORF. A mutation present at position 705 of the ß-globin intron activates two cryptic splice sites within the intron that lead to the production of a spliced luciferase mRNA that is disrupted by a small intron with an in-frame stop codon, thus preventing translation of functional luciferase protein. The transfection of a 2'OMe oligonucleotide complementary to the cryptic 705 splice site inhibits splicing at the cryptic splice sites enabling the complete removal of the ß-globin intron and production of a mRNA with a complete, uninterrupted luciferase ORF.

The HeLa-Luc 705 cell line was transfected with increasing amounts of the anti-705 splice site 2'OMe RNA oligo at the indicated final concentrations using the TransIT-Oligo Transfection Reagent. The cells were harvested 24 hours post-transfection and assayed for luciferase activity. The increase in luciferase activity indicates effective delivery of the anti-705 splice site RNA oligo using the TransIT-Oligo Reagent.

Keyword : V2160,MIR2160,V2164,MIR2164,V2165T,MIR2165,V2166,MIR2166
도입물질에 따른 도입시약
>
Large RNA & CRISPR guide RNA용transfection ..
TransIT®-mRNA Transfection Kit
>
mRNA, sgRNA, siRNA등 다양한 RNA transfection..
Xfect™ RNA Transfection Reagent